NASDAQFinancialsAsset ManagementSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS improves to at least $0.21 by Q3 2026 | A primary condition in US Global Investors Inc's published investment case. The stated target is >= $0.21. | Intact | EPS falls below $0.02 in any quarter through 2026-Q3 | Diluted EPS: $-0.02 per share FY2026-Q4; GAAP. Published target: >= $0.21. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Sep 3, 2026-0.0229 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Net income grows to at least $2.7 million by Q3 2026 | Net income improved from $315K to $2.7M, showing strong profit growth. | Intact | net income falls below $315K in any quarter through 2026-Q3 | Net income: $-283,000 FY2026-Q4; GAAP. Published target: >= $2.7 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Sep 3, 2026-283,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 4 quarters. Net income improved from a loss of $846,000 in 2026-Q2 to a profit of $2.7 million in 2026-Q1, then declined to a loss of $283,000 in 2026-Q4. Management emphasized net income growth in 2026-Q1, but the latest quarter shows a decline, indicating mixed delivery. Delivery assessment Oct 24, 2026 |
Revenue grows to at least $2.76 million by Q3 2026 | A primary condition in US Global Investors Inc's published investment case. The stated target is >= $2.76 million. | Intact | revenue falls below $2.16 million in any quarter through 2026-Q3 | Revenue: $-452,000 FY2026-Q4; GAAP. Published target: >= $2.76 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Sep 3, 2026-452,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 4 quarters. Revenue increased from $2.25 million in 2026-Q1 to $2.76 million in 2026-Q3, a 23% rise, then data for 2026-Q4 is unavailable. Management highlighted a 10% quarter-over-quarter and 31% year-over-year increase in 2026-Q1. The trajectory shows delivering revenue growth. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a small-cap financial business with a growth-oriented thesis, but recent performance makes it a higher-risk, watch-stage case rather than a proven compounder. Management appears stable, while earnings quality is fragile and results have been weak.
GROW is valued cheaply versus peers, and the expectations gap is negative, meaning expectations appear lower than the model’s baseline. The evidence labels this valuation as justified, with low fragility from what is priced in; that does not remove the risks from weak execution and sector headwinds.
Near term, revenue growth has been a positive, but net income has been uneven and the company has a run of earnings misses. Management’s focus on revenue growth is on track, while delivery on net income is mixed; a further guidance cut would add a meaningful concern.
Over the next several quarters, the thesis depends on revenue growth translating into steadier profits and management avoiding another guidance cut. Sector conditions also matter: continued strength from large financial firms could support momentum, while rate cuts from the current level could weigh on the sector.
Over the next 1 to 3 years, GROW’s long-term thesis has a low valuation versus peers but needs clearer, more consistent earnings delivery. The near-term evidence remains weak, so the thesis is in a watch state. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.